Good evening :)
$
₹
Opko Health Inc

Opko Health Inc

OPK

NASDAQ
Asset Logo

Opko Health Inc

OPK

NASDAQ
$1.561.57% (-0.02)
$
₹
$1.561.57% (-0.02)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
Loading...
1D
1W
1M
1Y
5Y
Max

Healthcare

Diagnostics & Research

Small Cap

With a market cap of $1.2B the stock is ranked 2633

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

1.00
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-0.07
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

93.64
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

-12.4%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast
Analyst Ratings & Forecast

Based on 7 analysts' reports

Buy
6 analysts
Hold
1 analyst
Sell
0 analyst

Analysts expect a +175.16% price upside over the next year

Current Price$1.56
Target Price$4.37

Company Profile

OPKO Health, Inc. operates as a healthcare company, in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company operates in two segments, Pharmaceutical and Diagnostics. The Pharmaceutical segment develops MDX2001, a tetra-specific antibody targeting several types of solid tumors in Phase 1 clinical trials; MDX2003, a tetra-specific antibody targeting two antigens for hematological tumors in Phase 1 clinical trials; and MDX2004, a trispecific immune modulator to rebuild and sustain the patient's own immune system. This segment also engages in the development of Epstein Barr Virus vaccine; Rayaldee, a patented extended-release product for oral administration containing 30 mcg of a prohormone; OPK-88006 oral and injectable product to regulate blood glucose and reduce body weight; NGENLA, recombinant human growth hormone product developed for the long-term treatment of pediatric patients with growth hormone deficiency. The Diagnostics segment offers laboratory testing services, such as detection, diagnosis, evaluation, monitoring, and treatment of diseases, as well as esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare under the BioReference brand; and 4Kscore test. OPKO Health, Inc. was founded in 2006 and is headquartered in Miami, Florida.
OPKO Health, Inc. operates as a healthcare company, in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company operates in two segments, Pharmaceutical and Diagnostics. The Pharmaceutical segment develops MDX2001, a tetra-specific antibody targeting several types of solid tumors in Phase 1 clinical trials; MDX2003, a tetra-specific antibody targeting two antigens for hematological tumors in Phase 1 clinical trials; and MDX2004, a trispecific immune modulator to rebuild and sustain the patient's own immune system. This segment also engages in the development of Epstein Barr Virus vaccine; Rayaldee, a patented extended-release product for oral administration containing 30 mcg of a prohormone; OPK-88006 oral and injectable product to regulate blood glucose and reduce body weight; NGENLA, recombinant human growth hormone product developed for the long-term treatment of pediatric patients with growth hormone deficiency. The Diagnostics segment offers laboratory testing services, such as detection, diagnosis, evaluation, monitoring, and treatment of diseases, as well as esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare under the BioReference brand; and 4Kscore test. OPKO Health, Inc. was founded in 2006 and is headquartered in Miami, Florida.

Peers

Peers

AbbVie Inc
ABBV
AbbVie Inc
P/E Ratio
72.44
72.44
1Y Return
23.12%
23.12%
Buy Reco %
57.14
57.14
Amgen Inc
AMGN
Amgen Inc
P/E Ratio
27.17
27.17
1Y Return
57.16%
57.16%
Buy Reco %
46.87
46.87
Gilead Sciences Inc
GILD
Gilead Sciences Inc
P/E Ratio
—
—
1Y Return
31.2%
31.2%
Buy Reco %
63.33
63.33
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
P/E Ratio
31.84
31.84
1Y Return
33.81%
33.81%
Buy Reco %
52.94
52.94
Regeneron Pharmaceuticals Inc
REGN
Regeneron Pharmaceuticals Inc
P/E Ratio
20.49
20.49
1Y Return
45.28%
45.28%
Buy Reco %
76.00
76.00

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareDiagnostics & Research

Valuation

Returns

Forecast

StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Opko Health Inc -1.0093.64
AbbVie Inc72.4450.450.37
Amgen Inc27.1720.542.13

Price Comparison

Price Comparison

1 Month

1 Year

5 Years

Loading...

Financials

Financials

Income

Balance Sheet

Cash Flow

151.6
21.6
148.4
-31.2
124.1
-54.8
163.5
-8.4
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue173.68182.18173.63183.63149.95156.80151.66148.45124.19163.58
Net Income-81.83-10.3024.8914.02-67.61-148.4421.63-31.25-54.84-8.41
Net Profit Margin-47.11%-5.65%14.33%7.63%-45.08%-94.66%14.26%-21.05%-44.16%-5.14%
See CostsAll values in $ Million

Frequently asked questions

Frequently asked questions

  1. Opko Health Inc (OPK) share price today is $1.56 as of September 9, 2026 at 9:24 PM IST. The stock touched a day high of $1.59 and a day low of $1.56.

  2. Opko Health Inc stock trades on NASDAQ under the ticker symbol OPK.

  3. Opko Health Inc's market capitalization is $1.22B as of September 9, 2026 at 9:24 PM IST.

  4. Opko Health Inc's price-to-earnings (P/E) ratio is N/A as of September 9, 2026.

  5. Opko Health Inc's price-to-book (P/B) ratio is 1.00 as of September 9, 2026.

  6. Yes, You can buy Opko Health Inc shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Opko Health Inc shares in three steps: 1. Search Opko Health Inc on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Opko Health Inc trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Opko Health Inc (OPK) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 6.3897 shares at the current price of $1.56.

Loading...